Obesity as a risk and prognostic factor for disease progression in intraductal papillary mucinous neoplasm (IPMN): A systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
6149 patients with IPMN.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] This meta-analysis reveals that obesity and overweight may be associated with the risk of progression of IPMN, as well as to the likelihood of malignancy in patients undergoing surgery for IPMN. Surveillance programs should therefore take obesity into account as a potential risk factor for progression of IPMNs.
[INTRODUCTION] Intraductal papillary mucinous neoplasms (IPMN) are a common precancerous condition for pancreatic cancer.
- 95% CI 1.01-6.11
- 연구 설계 Meta-analysis
APA
Parhiala M, Gustorff C, et al. (2026). Obesity as a risk and prognostic factor for disease progression in intraductal papillary mucinous neoplasm (IPMN): A systematic review and meta-analysis.. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 26(2), 272-278. https://doi.org/10.1016/j.pan.2026.01.009
MLA
Parhiala M, et al.. "Obesity as a risk and prognostic factor for disease progression in intraductal papillary mucinous neoplasm (IPMN): A systematic review and meta-analysis.." Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], vol. 26, no. 2, 2026, pp. 272-278.
PMID
41580331 ↗
Abstract 한글 요약
[INTRODUCTION] Intraductal papillary mucinous neoplasms (IPMN) are a common precancerous condition for pancreatic cancer. Obesity is an increasingly prevalent condition globally and has shown to contribute to carcinogenesis in pancreatic cancer. A potential effect of overweight and obesity on disease progression in IPMN is unexplored.
[METHODS] A systematic search of databases was performed up to April 2025. Inclusion criteria were original English studies reporting data on the prevalence of overweight and obesity in IPMN patients. Two independent reviewers performed study screening, data extraction and quality assessment using Covidence. Risk of bias assessment was done by using the Newcastle-Ottawa scale. Meta-analysis was performed of hazards ratios (HR) and odds ratios (OR) using a random-effects model with generic inverse variance method.
[RESULTS] After screening 695 studies a total of 15 cohort studies were included, entailing data on 6149 patients with IPMN. Four studies reported HR for progression of IPMN using different categories to report body-mass-index (BMI). The pooled HR for IPMN progression for obese versus normal-weight individuals was 1.87 (95 % confidence interval (CI) 1.42-2.45). Four studies reported OR for the association between obesity and malignancy in surgically treated IPMN patients. The pooled OR for malignancy was 2.48 (95 % CI 1.01-6.11).
[CONCLUSIONS] This meta-analysis reveals that obesity and overweight may be associated with the risk of progression of IPMN, as well as to the likelihood of malignancy in patients undergoing surgery for IPMN. Surveillance programs should therefore take obesity into account as a potential risk factor for progression of IPMNs.
[METHODS] A systematic search of databases was performed up to April 2025. Inclusion criteria were original English studies reporting data on the prevalence of overweight and obesity in IPMN patients. Two independent reviewers performed study screening, data extraction and quality assessment using Covidence. Risk of bias assessment was done by using the Newcastle-Ottawa scale. Meta-analysis was performed of hazards ratios (HR) and odds ratios (OR) using a random-effects model with generic inverse variance method.
[RESULTS] After screening 695 studies a total of 15 cohort studies were included, entailing data on 6149 patients with IPMN. Four studies reported HR for progression of IPMN using different categories to report body-mass-index (BMI). The pooled HR for IPMN progression for obese versus normal-weight individuals was 1.87 (95 % confidence interval (CI) 1.42-2.45). Four studies reported OR for the association between obesity and malignancy in surgically treated IPMN patients. The pooled OR for malignancy was 2.48 (95 % CI 1.01-6.11).
[CONCLUSIONS] This meta-analysis reveals that obesity and overweight may be associated with the risk of progression of IPMN, as well as to the likelihood of malignancy in patients undergoing surgery for IPMN. Surveillance programs should therefore take obesity into account as a potential risk factor for progression of IPMNs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.